国际放射医学核医学杂志
國際放射醫學覈醫學雜誌
국제방사의학핵의학잡지
INTERNATIONAL JOURNAL OF RADIATION MEDICINE AND NUCLEAR MEDICINE
2013年
1期
13-15,37
,共4页
刘晓秋%王芹%周则卫%韩英%王德芝%沈秀
劉曉鞦%王芹%週則衛%韓英%王德芝%瀋秀
류효추%왕근%주칙위%한영%왕덕지%침수
肝肿瘤%辐射增敏剂%剂量效应关系,药物%模型,动物%小鼠
肝腫瘤%輻射增敏劑%劑量效應關繫,藥物%模型,動物%小鼠
간종류%복사증민제%제량효응관계,약물%모형,동물%소서
Hepatoma%Radiation-sensitizing agents%Dose-response relationship,drug%Model,animal%Mice
目的 探讨9401对H22肝癌小鼠的放射增敏作用.方法 建立H22肝癌小鼠模型,按照给药和照射的不同,分为空白对照组、单纯照射组、烟酰胺联合照射组、9401高剂量联合照射组、9401中剂量联合照射组和9401低剂量联合照射组.照射后观察H22肝癌小鼠的肿瘤生长情况、记录肿瘤照射后的生长时间,并计算肿瘤生长的延迟时间和各组的放射增敏系数.照射后28 d处死小鼠,剥瘤称重,计算抑瘤率.结果 9401高、中、低各剂量联合照射组均能延缓肿瘤生长,其中9401高、中剂量联合照射组与烟酰胺联合照射组相比,差异有统计学意义(t=24.7和7.5,P均<0.01),且9401高、中剂量组辐射敏感性均显著增高,增敏系数分别为2.13、1.73,明显高于烟酰胺联合照射组的增敏系数1.61,差异有统计学意义(t=2.26和9.04,P均<0.05);9401高、中、低各剂量联合照射组的抑瘤率分别为64.5%、50.9%、42.6%,烟酰胺联合照射组的抑瘤率为53.2%,9401高剂量组抑瘤效果显著高于烟酰胺联合照射组,差异有统计学意义(t=2.8,P<0.05).9401高、中、低各剂量组与单纯照射组相比,抑瘤率差异有统计学意义(t=5.7,4.0和2.2,P均<0.05).结论 9401对H22肝癌小鼠肿瘤生长有明显的抑制作用,抑制肿瘤作用随给药剂量的增加而逐步增强,放射增敏效果显著,临床应用前景广阔.
目的 探討9401對H22肝癌小鼠的放射增敏作用.方法 建立H22肝癌小鼠模型,按照給藥和照射的不同,分為空白對照組、單純照射組、煙酰胺聯閤照射組、9401高劑量聯閤照射組、9401中劑量聯閤照射組和9401低劑量聯閤照射組.照射後觀察H22肝癌小鼠的腫瘤生長情況、記錄腫瘤照射後的生長時間,併計算腫瘤生長的延遲時間和各組的放射增敏繫數.照射後28 d處死小鼠,剝瘤稱重,計算抑瘤率.結果 9401高、中、低各劑量聯閤照射組均能延緩腫瘤生長,其中9401高、中劑量聯閤照射組與煙酰胺聯閤照射組相比,差異有統計學意義(t=24.7和7.5,P均<0.01),且9401高、中劑量組輻射敏感性均顯著增高,增敏繫數分彆為2.13、1.73,明顯高于煙酰胺聯閤照射組的增敏繫數1.61,差異有統計學意義(t=2.26和9.04,P均<0.05);9401高、中、低各劑量聯閤照射組的抑瘤率分彆為64.5%、50.9%、42.6%,煙酰胺聯閤照射組的抑瘤率為53.2%,9401高劑量組抑瘤效果顯著高于煙酰胺聯閤照射組,差異有統計學意義(t=2.8,P<0.05).9401高、中、低各劑量組與單純照射組相比,抑瘤率差異有統計學意義(t=5.7,4.0和2.2,P均<0.05).結論 9401對H22肝癌小鼠腫瘤生長有明顯的抑製作用,抑製腫瘤作用隨給藥劑量的增加而逐步增彊,放射增敏效果顯著,臨床應用前景廣闊.
목적 탐토9401대H22간암소서적방사증민작용.방법 건립H22간암소서모형,안조급약화조사적불동,분위공백대조조、단순조사조、연선알연합조사조、9401고제량연합조사조、9401중제량연합조사조화9401저제량연합조사조.조사후관찰H22간암소서적종류생장정황、기록종류조사후적생장시간,병계산종류생장적연지시간화각조적방사증민계수.조사후28 d처사소서,박류칭중,계산억류솔.결과 9401고、중、저각제량연합조사조균능연완종류생장,기중9401고、중제량연합조사조여연선알연합조사조상비,차이유통계학의의(t=24.7화7.5,P균<0.01),차9401고、중제량조복사민감성균현저증고,증민계수분별위2.13、1.73,명현고우연선알연합조사조적증민계수1.61,차이유통계학의의(t=2.26화9.04,P균<0.05);9401고、중、저각제량연합조사조적억류솔분별위64.5%、50.9%、42.6%,연선알연합조사조적억류솔위53.2%,9401고제량조억류효과현저고우연선알연합조사조,차이유통계학의의(t=2.8,P<0.05).9401고、중、저각제량조여단순조사조상비,억류솔차이유통계학의의(t=5.7,4.0화2.2,P균<0.05).결론 9401대H22간암소서종류생장유명현적억제작용,억제종류작용수급약제량적증가이축보증강,방사증민효과현저,림상응용전경엄활.
Objective To investigate the radiosensitizing effects of 9401 on mice bearing H22hepatoma.Methods Mouse model bearing H22 hepatoma cells were established.Mice were randomly divided into six groups,the control group,the radiation group and four treatment groups including 9401 at high,medium and low dosages and nicotinamide combined with radiation.After irradiated,the growth of tumor was observed,the time of tumor growth was recorded,the delay time of tumor growth and enhancement factor(EF)were calculated.After 28 days,the mice were killed,the tumors were stripped and inhibition rate was calculated.Results Groups of 9401 combined with radiation could pestpone tumor growth.The difference was statistically significant between 9401 groups at high,medium dosages combined with radiation and nicotinamide combined with radiation group (t=24.7 and 7.5,both P<0.01).Compared with radiation alone group,groups of 9401 combined with radiation had significant radiosensitizing effect.The enhancement factor of 9401 combined with radiation groups at high and medium dosages were 2.13 and 1.73 respectively,they were significant higher than nicotinamide combined with radiation group (t=2.26 and 9.04,both P<0.05).The inhibition rate of 9401 groups at high,medium and low dosages combined with radiation were 64.5%,50.9% and 42.6% respectively.The inhibition rate of nicotinamide group combined radiation was 53.2%.The inhibition rate of 9401 at high dosage combined with radiation had significant difference with nicotinamide combined radiation (t =2.8.P<0.05).Nicotinamide combined with radiation group,9401 combined with radiation groups could significant inhibit the growth of tumors compared with radiation alone group (t=5.7,4.0 and 2.2,all P<0.05).Conclusion 9401 can inhibit the tumor growth and the inhibition effect increases gradually with the drug dose increasing.It also has radiosensitizing effects on mice bearing H22hepatoma and present broadly clinical practice prospect.